CD147-expressed small extracellular vesicles enhance the detection of colorectal neoplasia with fecal immunochemical test

L.-C. Chang , B.-R. Lin , H.-M. Chiu , M.-S. Wu , T. Ochiya , T.-L. Shen
{"title":"CD147-expressed small extracellular vesicles enhance the detection of colorectal neoplasia with fecal immunochemical test","authors":"L.-C. Chang ,&nbsp;B.-R. Lin ,&nbsp;H.-M. Chiu ,&nbsp;M.-S. Wu ,&nbsp;T. Ochiya ,&nbsp;T.-L. Shen","doi":"10.1016/j.esmogo.2025.100140","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Blood testing increases adherence to colorectal cancer (CRC) screening. The suboptimal detection of advanced adenoma (AA) and early-stage CRC by blood tests limits their application. The current study aims to investigate the diagnostic performance of CD147-expressed small extracellular vesicles (CD147) in the serum in combination with the fecal immunochemical test (FIT) for detecting AA and CRC.</div></div><div><h3>Patients and methods</h3><div>The case-control study enrolled 15 healthy controls and 50 CRC patients in the training cohort and 120 healthy controls, 50 non-AA patients, 50 AA patients, and 60 CRC patients in the validation cohort. CD147 was detected using the ExoScreen assay. The sensitivity and specificity of CD147 alone and combined with the FIT for detecting colorectal neoplasia were compared.</div></div><div><h3>Results</h3><div>CD147 could detect AA and CRC with a sensitivity of 58.0% and 71.7%, respectively. Combined with a 1-day FIT, the sensitivity for detecting AA and CRC would increase to 78.0% and 93.3%, respectively. Moreover, CD147 with 1-day FIT had a higher sensitivity than 1-day FIT alone for detecting proximal CRC (100% versus 89.5%). Besides, CD147 may detect 57.7% and 50.0% of the AA and CRC that FIT failed to detect, respectively. However, the specificity and false-positive rate of CD147 were inferior to those of FIT for detecting AA and CRC.</div></div><div><h3>Conclusions</h3><div>CD147 is superior to FIT for detecting AA and proximal neoplasia. Moreover, CD147 can increase the sensitivity of FIT for detecting either AA or CRC by combinatory use. However, false positivity is the concern of CD147, which should be further resolved in the future.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100140"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819825000093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Blood testing increases adherence to colorectal cancer (CRC) screening. The suboptimal detection of advanced adenoma (AA) and early-stage CRC by blood tests limits their application. The current study aims to investigate the diagnostic performance of CD147-expressed small extracellular vesicles (CD147) in the serum in combination with the fecal immunochemical test (FIT) for detecting AA and CRC.

Patients and methods

The case-control study enrolled 15 healthy controls and 50 CRC patients in the training cohort and 120 healthy controls, 50 non-AA patients, 50 AA patients, and 60 CRC patients in the validation cohort. CD147 was detected using the ExoScreen assay. The sensitivity and specificity of CD147 alone and combined with the FIT for detecting colorectal neoplasia were compared.

Results

CD147 could detect AA and CRC with a sensitivity of 58.0% and 71.7%, respectively. Combined with a 1-day FIT, the sensitivity for detecting AA and CRC would increase to 78.0% and 93.3%, respectively. Moreover, CD147 with 1-day FIT had a higher sensitivity than 1-day FIT alone for detecting proximal CRC (100% versus 89.5%). Besides, CD147 may detect 57.7% and 50.0% of the AA and CRC that FIT failed to detect, respectively. However, the specificity and false-positive rate of CD147 were inferior to those of FIT for detecting AA and CRC.

Conclusions

CD147 is superior to FIT for detecting AA and proximal neoplasia. Moreover, CD147 can increase the sensitivity of FIT for detecting either AA or CRC by combinatory use. However, false positivity is the concern of CD147, which should be further resolved in the future.
表达cd147的细胞外小泡增强粪便免疫化学试验对结直肠肿瘤的检测
血液检测增加了结直肠癌(CRC)筛查的依从性。晚期腺瘤(AA)和早期CRC的血液检测不理想,限制了它们的应用。本研究旨在探讨血清中表达CD147的小细胞外囊泡(CD147)结合粪便免疫化学试验(FIT)对AA和CRC的诊断价值。患者和方法病例对照研究纳入了15名健康对照者和50名结直肠癌患者作为训练组,120名健康对照者、50名非AA患者、50名AA患者和60名结直肠癌患者作为验证组。使用ExoScreen法检测CD147。比较CD147与FIT联合检测结直肠肿瘤的敏感性和特异性。结果scd147检测AA和CRC的灵敏度分别为58.0%和71.7%。结合1天FIT,检测AA和CRC的灵敏度分别提高到78.0%和93.3%。此外,CD147与1天FIT相比,在检测近端结直肠癌方面具有更高的敏感性(100%对89.5%)。此外,CD147可以分别检测到FIT未检测到的57.7%和50.0%的AA和CRC。然而,CD147检测AA和CRC的特异性和假阳性率低于FIT。结论scd147在检测AA和近端肿瘤方面优于FIT。此外,CD147联合使用可提高FIT检测AA或CRC的灵敏度。然而,假阳性是CD147关注的问题,这在未来需要进一步解决。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信